Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
Opthea (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company focusing on novel therapies for retinal diseases like wet age-related macular degeneration (wet AMD), has announced its participation in the UBS Virtual Ophthalmology Day 2024. The event is scheduled for October 2, 2024.
Key details of Opthea's participation include:
- A fireside chat on Wednesday, October 2, 2024, at 4:00 PM ET
- CEO Frederic Guerard, PharmD, will be the presenter
- One-on-one investor meetings will be available
- A webcast link is provided for access to the fireside chat
The webcast will also be accessible through the 'Events & Presentations' section of Opthea's Investor Relations webpage at www.opthea.com.
Opthea (ASX/NASDAQ: OPT), un'azienda biofarmaceutica in fase clinica focalizzata su nuove terapie per le malattie retiniche come la degenerazione maculare legata all'età umida (wet AMD), ha annunciato la sua partecipazione al UBS Virtual Ophthalmology Day 2024. L'evento è programmato per il 2 ottobre 2024.
I punti salienti della partecipazione di Opthea includono:
- Un incontro informale mercoledì 2 ottobre 2024, alle 16:00 ET
- Il CEO Frederic Guerard, PharmD, sarà il relatore
- Saranno disponibili incontri individuali con gli investitori
- Un link per il webcast sarà fornito per accedere all'incontro informale
Il webcast sarà anche accessibile attraverso la sezione 'Eventi e Presentazioni' della pagina delle Relazioni con gli Investitori di Opthea su www.opthea.com.
Opthea (ASX/NASDAQ: OPT), una empresa biofarmacéutica en etapa clínica que se enfoca en nuevas terapias para enfermedades retinianas como la degeneración macular relacionada con la edad húmeda (wet AMD), ha anunciado su participación en el UBS Virtual Ophthalmology Day 2024. El evento está programado para el 2 de octubre de 2024.
Los detalles clave de la participación de Opthea incluyen:
- Un chat íntimo el miércoles 2 de octubre de 2024, a las 4:00 PM ET
- El CEO Frederic Guerard, PharmD, será el presentador
- Habrá reuniones individuales con inversores disponibles
- Se proporcionará un enlace para el webcast para acceder al chat
El webcast también estará disponible a través de la sección 'Eventos y Presentaciones' en la página de Relaciones con Inversores de Opthea en www.opthea.com.
Opthea (ASX/NASDAQ: OPT)는 습성 노인성 황반변성 (wet AMD)과 같은 망막 질환에 대한 새로운 치료법에 집중하는 임상 단계의 생명공학 회사로서 UBS 가상 안과의 날 2024에 참여한다고 발표했습니다. 이 행사는 2024년 10월 2일로 예정되어 있습니다.
Opthea의 참여 주요 사항은 다음과 같습니다:
- 2024년 10월 2일 수요일 오후 4:00 ET에 불꽃놀이 대화가 진행됩니다.
- CEO Frederic Guerard, PharmD가 발표할 예정입니다.
- 투자자와의 1:1 미팅이 가능합니다.
- 불꽃놀이 대화에 대한 접근을 위한 웹캐스트 링크가 제공됩니다.
웹캐스트는 www.opthea.com의 Opthea 투자자 관계 웹페이지의 '이벤트 및 프레젠테이션' 섹션을 통해서도 접근할 수 있습니다.
Opthea (ASX/NASDAQ: OPT), une entreprise biopharmaceutique en phase clinique axée sur les nouvelles thérapies pour les maladies rétiniennes telles que la dégénérescence maculaire liée à l'âge humide (wet AMD), a annoncé sa participation au UBS Virtual Ophthalmology Day 2024. L'événement est prévu pour le 2 octobre 2024.
Les détails clés de la participation d'Opthea comprennent :
- Une discussion informelle le mercredi 2 octobre 2024 à 16h00 ET
- Le PDG Frederic Guerard, PharmD, sera le présentateur
- Des réunions individuelles avec les investisseurs seront disponibles
- Un lien vers le webcast sera fourni pour accéder à la discussion informelle
Le webcast sera également accessible via la section 'Événements et Présentations' de la page des Relations avec les Investisseurs d'Opthea à www.opthea.com.
Opthea (ASX/NASDAQ: OPT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf neuartige Therapien für Netzhauterkrankungen wie die feuchte altersbedingte Makuladegeneration (wet AMD) konzentriert, hat seine Teilnahme am UBS Virtuellen Ophthalmologietag 2024 bekannt gegeben. Die Veranstaltung ist für den 2. Oktober 2024 angesetzt.
Wichtige Details zur Teilnahme von Opthea umfassen:
- Ein informelles Gespräch am Mittwoch, den 2. Oktober 2024, um 16:00 Uhr ET
- CEO Frederic Guerard, PharmD, wird der Referent sein
- Es werden individuelle Investorengespräche angeboten
- Ein Webcast-Link wird zur Verfügung gestellt, um auf das informelle Gespräch zuzugreifen
Der Webcast wird auch über den Bereich 'Veranstaltungen und Präsentationen' auf der Investor Relations-Webseite von Opthea unter www.opthea.com zugänglich sein.
- None.
- None.
MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in a fireside chat and be available for one-on-one investor meetings at the UBS Virtual Ophthalmology Day 2024 being held on October 2, 2024.
UBS Virtual Ophthalmology Day 2024
| Fireside chat: | Wednesday, October 2, 2024, 4:00 PM ET |
| Presenter: | Frederic Guerard, PharmD, CEO |
| Webcast link: | https://kvgo.com/ubs/opthea-ltd-oct-2024 |
The webcast can also be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website, www.opthea.com.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Investor Inquiries
PJ Kelleher
LifeSci Advisors, LLC
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579
Media Inquiries
Silvana Guerci-Lena
NorthStream Global Partners
Email: silvana@nsgpllc.com
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited
FAQ
When is Opthea (OPT) participating in the UBS Virtual Ophthalmology Day 2024?
Who will represent Opthea (OPT) at the UBS Virtual Ophthalmology Day 2024?
What type of retinal disease is Opthea (OPT) focusing on in their drug development?
How can investors access Opthea's (OPT) presentation at the UBS Virtual Ophthalmology Day 2024?
